Abstract 481P
Background
Identifying actionable driver mutations via tissue-based comprehensive genomic profiling (CGP) is paramount in treatment decisions for metastatic non-squamous, non-small cell lung cancer (NSCLC). Here, we elucidate the feasibility of CGP in early-stage NSCLC, and compare the tumor mutational burden (TMB) and mutation landscape using three different platforms.
Methods
Surgically resected NSCLC samples (N=96) collected between October 2011 and April 2020 at Yonsei Cancer Center were analyzed using whole-exome sequencing (WES) (Illumina DRAGEN, v3.8) (N=96), TruSight Oncology 500 (TSO500, v2.0) (for research use only) (Illumina) (N=96), and Foundation One CDx Assay (F1CDx) (N=26) to assess the concordance in TMB calculation and targetable mutations. Programmed death-ligand 1 (PD-L1) expression were evaluated using Vectra Polaris (Akoya).
Results
The stage distribution after surgery was 80% I (N=77) and 20% II (N=19). Ninety-nine percent (N=95) were adenocarcinoma. All 96 samples were analyzed with WES and TSO500. Among these samples, 26 samples were analyzed with F1CDx. The median TMB with WES and TSO500 was 1.57 and 4.7 mut/Mb, respectively (p<0.05). The median TMB was 1.88, 5.5, 4 mut/Mb for WES, TSO500 and F1CDx, respectively (p=0.0048). Linear regression analysis of TMB values calculated using concordance correlation coefficient (CCC) between WES and TSO500 resulted in a R2=0.76. For PD-L1 tumor proportion score (TPS) of <1% (negative, N=18), ≥1% (low, N=68) and ≥ 50% (high, N=10), the CCC were 0.075, 0.79, and 0.95, respectively. The CCC values for TMB concordance were variable between 3 platforms (WES vs. TSO500, R2=0.87; WES v. F1CDx, R2=0.72; TSO500 vs. F1CDx, R2=0.84). Mutation landscape revealed EGFR mutation (51%, N=49) as the most common actionable driver mutation, comprising of L858R (N=22), E19del (N=20), and other non-common EGFR mutations (N=7).
Conclusions
F1CDx and TSO500 showed robust analytical performance for TMB assessment with TSO500 showing stronger concordance of TMB with high PD-L1 expression. As paradigm for early-resected NSCLC continues to evolve, understanding TMB and mutation landscape may help advance clinical outcomes for this subset of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yonsei Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract